Cal Cohen 

AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England, about new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke.

Double click for the full interview (14 minutes):


Or hear part I about Isentress, Merck’s new integrase inhibitor (4 minutes):


Or hear part II about elvitegravir, Gilead’s new integrase inhibitor (2 minutes):


Or hear part III about maraviroc, Pfizer’s new CCR5 inhibitor (5 minutes):


Or hear part IV about TMC-278, Tibotec’s new non-nuke (3 minutes):


Or click here to read the full transcript of the interview.